Alibaba Stock Soars on AI Frenzy – Can the Rally Last?

Alibaba (BABA) sinks ~3.8% at the close after White House memo allegations; France flags AliExpress; class‑action probe announced — Nov. 14, 2025

Alibaba’s U.S.-listed shares finished Friday sharply lower after fresh geopolitical and regulatory headlines weighed on sentiment into the bell.

Key takeaways (Nov. 14, 2025, after market close, ~4:00 p.m. ET)

  • Close: BABA $153.85, down about 3.75% on the day; session range: $151.79–$162.62. In post‑market trading, shares hovered near the close. [1]
  • Catalyst 1: Reuters, citing the Financial Times, reported a White House national security memo alleging Alibaba has provided tech support to China’s military; Alibaba denied the claims. [2]
  • Catalyst 2: France’s consumer watchdog said AliExpress (an Alibaba platform) and other marketplaces were found selling illicit products, escalating European scrutiny. [3]
  • Catalyst 3: The Rosen Law Firm announced a securities class‑action investigation tied to today’s headlines. [4]
  • Next date to watch: Alibaba said it will report September‑quarter results on Nov. 25, 2025. [5]

What moved Alibaba stock today

White House memo report and company denial.
Reuters reported that a White House memo—citing declassified intelligence—alleges Alibaba supported Chinese military operations; the company called the assertions “completely false.” The political sensitivity of the claim and the prospect of further scrutiny spurred selling through the afternoon. [6]

Fresh European pressure on marketplaces.
In Paris, France’s DGCCRF said AliExpress and peers were found listing prohibited items (including child‑like sex dolls and weapons), with referrals to prosecutors and calls for EU‑level coordination. While the probe encompasses multiple platforms, AliExpress’ inclusion added to Alibaba’s regulatory overhang in a key international market. [7]

Plaintiffs’ bar mobilizes.
After the memo headlines, the Rosen Law Firm publicized a class‑action investigation focused on Alibaba’s disclosures—an early legal step that, while not determinative, can keep headline risk elevated. [8]


Price action at a glance

  • Close:$153.85 (‑3.75% vs. prior close $159.84).
  • Intraday range:$151.79–$162.62—a wide swing that reflects the day’s headline volatility.
  • After‑hours: Trading remained near $153.8 shortly after the close. [9]

For context, BABA’s 52‑week range stands at $80.06–$192.67, underscoring how far the shares have rallied this year while remaining vulnerable to policy and regulatory news flow. [10]


The broader market backdrop

Markets were already on edge as risk assets sagged globally Friday on fading hopes for a near‑term Fed rate cut; tech leadership wobbled and macro caution was the tone across regions. That weaker tape compounded Alibaba’s single‑stock news pressure. [11]


What comes next

  • Earnings (Nov. 25): With results due in 11 days, investors will look for updates on China commerce trends, Singles’ Day read‑throughs, and the pace/returns of Alibaba’s multiyear AI and cloud investments. Management’s color on international commerce (AliExpress, Lazada) and regulatory compliance in Europe will also be in focus. [12]
  • Policy risk monitoring: Any follow‑up from Washington to the memo report—or formal EU actions following France’s findings—could influence the multiple near term. [13]
  • Legal overhang: Early class‑action announcements often precede filings and amendments; while many cases never materially impact fundamentals, they can add headline volatility. [14]

Bottom line

Today’s drop in Alibaba shares was driven primarily by policy and regulatory headlines rather than company fundamentals. With earnings around the corner and macro risk still in the frame, near‑term trading in BABA is likely to remain sensitive to Washington–Beijing news and European enforcement updates, even as investors await hard data on profitability and AI/cloud returns. [15]

This article is for informational purposes only and is not investment advice.

The best way to play AI is to buy the big hyperscalers, says Lead Edge Capital's Mitchell Green

References

1. www.investing.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.businesswire.com, 5. www.businesswire.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.businesswire.com, 9. www.investing.com, 10. www.investing.com, 11. www.reuters.com, 12. www.businesswire.com, 13. www.reuters.com, 14. www.businesswire.com, 15. www.reuters.com

Stock Market Today

  • Merck to Acquire Cidara Therapeutics for $9.2 Billion in Cash
    November 14, 2025, 6:32 PM EST. Merck (MRK) agreed to acquire Cidara Therapeutics (CDTX) for $9.2 billion in an all-cash deal at $221.50 per share, a 109% premium to yesterday's close. The deal gives Merck access to CD388, a promising influenza drug candidate in Phase 3. It's expected to close in Q1 next year and will be accounted for as an asset acquisition. Cidara stock surged ~105% to about $218, their highest in nine years, while Merck rose ~1%. This illustrates how a major pharma may pay a premium for rare assets with growth potential, though biotech bets carry execution risk if trials fail.
Palantir (PLTR) Jumps as Burry–Karp Spat Heats Up: Fresh Q3 Numbers, Lofty Valuation, and the Bull‑vs‑Bear Case — Nov. 10, 2025
Previous Story

Palantir (PLTR) Stock Today: Closes at $174.05 on Nov. 14, 2025 as Analyst Caution Meets U.K. Defense Push

Go toTop